Insider Selling: Illumina (NASDAQ:ILMN) Director Sells $15,172,478.62 in Stock

Illumina, Inc. (NASDAQ:ILMN) Director Keith Meister sold 104,393 shares of the business’s stock in a transaction dated Thursday, May 14th. The shares were sold at an average price of $145.34, for a total value of $15,172,478.62. Following the completion of the transaction, the director owned 3,500,048 shares in the company, valued at $508,696,976.32. This trade represents a 2.90% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Illumina Stock Performance

Shares of ILMN stock opened at $142.54 on Friday. The stock has a market capitalization of $21.57 billion, a PE ratio of 25.92, a price-to-earnings-growth ratio of 2.36 and a beta of 1.42. Illumina, Inc. has a 52-week low of $78.55 and a 52-week high of $155.53. The stock’s 50-day moving average price is $128.58 and its 200 day moving average price is $129.52. The company has a quick ratio of 1.36, a current ratio of 1.75 and a debt-to-equity ratio of 0.56.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings results on Thursday, April 30th. The life sciences company reported $1.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.05 by $0.10. The firm had revenue of $1.09 billion for the quarter, compared to analysts’ expectations of $1.07 billion. Illumina had a return on equity of 31.01% and a net margin of 19.42%.The firm’s revenue for the quarter was up 4.8% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.97 EPS. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. As a group, equities research analysts forecast that Illumina, Inc. will post 5.2 EPS for the current year.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on ILMN. Daiwa Securities Group upgraded Illumina from a “neutral” rating to an “outperform” rating and set a $155.00 price target on the stock in a research report on Thursday. Stifel Nicolaus boosted their price target on Illumina from $135.00 to $155.00 and gave the company a “buy” rating in a research report on Tuesday, January 20th. Evercore reiterated an “outperform” rating on shares of Illumina in a research report on Friday, May 1st. UBS Group reiterated a “neutral” rating and set a $135.00 target price on shares of Illumina in a research report on Friday, February 6th. Finally, Weiss Ratings cut Illumina from a “hold (c)” rating to a “hold (c-)” rating in a research report on Wednesday, April 29th. Seven investment analysts have rated the stock with a Buy rating, nine have issued a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $137.75.

Hedge Funds Weigh In On Illumina

Several institutional investors and hedge funds have recently added to or reduced their stakes in ILMN. Elyxium Wealth LLC acquired a new position in Illumina during the 4th quarter worth approximately $25,000. Board of the Pension Protection Fund acquired a new position in Illumina during the 4th quarter worth approximately $26,000. Creative Capital Management Investments LLC increased its position in Illumina by 160.0% during the 4th quarter. Creative Capital Management Investments LLC now owns 195 shares of the life sciences company’s stock worth $26,000 after purchasing an additional 120 shares during the period. TD Waterhouse Canada Inc. acquired a new stake in shares of Illumina in the 4th quarter worth approximately $26,000. Finally, Laurel Wealth Advisors LLC acquired a new stake in shares of Illumina in the 4th quarter worth approximately $26,000. Institutional investors and hedge funds own 89.42% of the company’s stock.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.